\BOOKMARK [0][-]{chapter*.1}{Abstract}{}% 1
\BOOKMARK [0][-]{chapter*.2}{Preface}{}% 2
\BOOKMARK [0][-]{chapter*.3}{Table of Contents}{}% 3
\BOOKMARK [0][-]{chapter*.4}{List of Tables}{}% 4
\BOOKMARK [0][-]{chapter*.5}{List of Figures}{}% 5
\BOOKMARK [0][-]{chapter*.6}{List of Abbreviations}{}% 6
\BOOKMARK [0][-]{chapter*.7}{Acknowledgments}{}% 7
\BOOKMARK [0][-]{chapter.1}{1 Introduction}{}% 8
\BOOKMARK [1][-]{section.1.1}{1.1 Cancer as a Genetic Disease}{chapter.1}% 9
\BOOKMARK [1][-]{section.1.2}{1.2 The Evolution of Molecular Diagnostics in Cancer}{chapter.1}% 10
\BOOKMARK [1][-]{section.1.3}{1.3 The Era of Precision Oncology}{chapter.1}% 11
\BOOKMARK [1][-]{section.1.4}{1.4 Next-generation Sequencing Technologies}{chapter.1}% 12
\BOOKMARK [1][-]{section.1.5}{1.5 Applications of Next-generation Sequencing}{chapter.1}% 13
\BOOKMARK [2][-]{subsection.1.5.1}{1.5.1 Targeted Sequencing}{section.1.5}% 14
\BOOKMARK [2][-]{subsection.1.5.2}{1.5.2 Whole Exome Sequencing}{section.1.5}% 15
\BOOKMARK [2][-]{subsection.1.5.3}{1.5.3 Whole Genome Sequencing}{section.1.5}% 16
\BOOKMARK [1][-]{section.1.6}{1.6 Variant Calling Pipeline}{chapter.1}% 17
\BOOKMARK [1][-]{section.1.7}{1.7 Germline Variants in The Tumour Genome}{chapter.1}% 18
\BOOKMARK [2][-]{subsection.1.7.1}{1.7.1 Incidental Findings}{section.1.7}% 19
\BOOKMARK [2][-]{subsection.1.7.2}{1.7.2 Pharmacogenomic Variants}{section.1.7}% 20
\BOOKMARK [2][-]{subsection.1.7.3}{1.7.3 Challenges}{section.1.7}% 21
\BOOKMARK [1][-]{section.1.8}{1.8 ACCE Model Process for Evaluating Genetic Tests}{chapter.1}% 22
\BOOKMARK [1][-]{section.1.9}{1.9 Objectives}{chapter.1}% 23
\BOOKMARK [0][-]{chapter.2}{2 Materials and Methods}{}% 24
\BOOKMARK [1][-]{section.2.1}{2.1 Overview of study design}{chapter.2}% 25
\BOOKMARK [1][-]{section.2.2}{2.2 Patient samples}{chapter.2}% 26
\BOOKMARK [1][-]{section.2.3}{2.3 Sample preparation, library construction, and Illumina sequencing}{chapter.2}% 27
\BOOKMARK [1][-]{section.2.4}{2.4 OncoPanel \(Amplicon-based targeted sequencing panel for solid tumours\)}{chapter.2}% 28
\BOOKMARK [1][-]{section.2.5}{2.5 Variant calling pipeline}{chapter.2}% 29
\BOOKMARK [2][-]{subsection.2.5.1}{2.5.1 Read alignment and variant calling}{section.2.5}% 30
\BOOKMARK [2][-]{subsection.2.5.2}{2.5.2 Variant filtering}{section.2.5}% 31
\BOOKMARK [2][-]{subsection.2.5.3}{2.5.3 Variant annotation and interpretation}{section.2.5}% 32
\BOOKMARK [1][-]{section.2.6}{2.6 Sequence analysis}{chapter.2}% 33
\BOOKMARK [1][-]{section.2.7}{2.7 Application of VAF thresholds to separate germline alterations from somatic mutations}{chapter.2}% 34
\BOOKMARK [0][-]{chapter.3}{3 Assessment of Formalin-Induced DNA Damage in FFPE Specimens}{}% 35
\BOOKMARK [1][-]{section.3.1}{3.1 Comparison of efficiency in amplicon enrichment and sequencing results between blood and FFPE specimens}{chapter.3}% 36
\BOOKMARK [1][-]{section.3.2}{3.2 Reduced coverage depth in FFPE specimens is more pronounced for longer amplicons}{chapter.3}% 37
\BOOKMARK [1][-]{section.3.3}{3.3 Deamination effects lead to increased C>T/G>A transitions in FFPE specimens}{chapter.3}% 38
\BOOKMARK [1][-]{section.3.4}{3.4 Increased age of paraffin block results in reduced amplicon yield and elevated level of C>T/G>A sequence artifacts}{chapter.3}% 39
\BOOKMARK [0][-]{chapter.4}{4 Identification of Germline Alterations in FFPE Tumours}{}% 40
\BOOKMARK [1][-]{section.4.1}{4.1 Frequency and variant assessment of germline alterations in patients from TOP cohort}{chapter.4}% 41
\BOOKMARK [1][-]{section.4.2}{4.2 Germline alterations are highly concordant between blood and FFPE specimens}{chapter.4}% 42
\BOOKMARK [1][-]{section.4.3}{4.3 Application of tumour content to separate germline alterations from somatic mutations in tumour-only analyses}{chapter.4}% 43
\BOOKMARK [0][-]{chapter.5}{5 Discussion}{}% 44
\BOOKMARK [0][-]{chapter.6}{6 Conclusion}{}% 45
\BOOKMARK [0][-]{chapter*.39}{Bibliography}{}% 46
\BOOKMARK [0][-]{appendix.A}{A Supporting Materials}{}% 47
